CardioTeca CardioTeca CardioTeca CardioTeca
ESPACIO Arritmias

Biblioteca de referencias

Detalles
G
ESPACIO de arritmias › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

Descargar en RIS (277 referencias)

Artículos y guías en PubMed (244)

  1. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138(13):e272-e391. doi:10.1161/CIR.0000000000000549 · PMID 29084731G1
  2. Alabed S, Sabouni A, Providencia R, Atallah E, Qintar M, Chico TJ. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Database Syst Rev. 2017;10(10):CD005154. doi:10.1002/14651858.CD005154.pub4 · PMID 29025197I1
  3. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351(23):2384-91. doi:10.1056/NEJMoa041233 · PMID 15575054I1
  4. Amara N, Boveda S, Defaye P, Klug D, Treguer F, Amet D, et al. Implantable cardioverter-defibrillator therapy among patients with non-ischaemic vs. ischaemic cardiomyopathy for primary prevention of sudden cardiac death. Europace. 2018;20(1):65-72. doi:10.1093/europace/euw379 · PMID 28082419G3
  5. Andrade JG, Wells GA, Deyell MW, Bennett M, Essebag V, Champagne J, et al. Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2021;384(4):305-315. doi:10.1056/NEJMoa2029980 · PMID 33197159G2
  6. Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, Cequier Fillat Á, Roldán Rabadán I, Muñiz García J, et al. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev Esp Cardiol (Engl Ed). 2020;73(1):14-20. doi:10.1016/j.rec.2019.02.021 · PMID 31160265G3
  7. Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337(22):1576-83. doi:10.1056/NEJM199711273372202 · PMID 9411221G2
  8. Arana-Rueda E, Rubio-Campal JM, Campos B, Rodríguez-Entem F, Calvo D, collaborators of the Spanish catheter ablation registry. Spanish catheter ablation registry. 24th official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2024). Rev Esp Cardiol (Engl Ed). 2025;78(12):1088-1099. doi:10.1016/j.rec.2025.08.009 · PMID 41076237G3
  9. Arbelo E, Brugada J, Blomström-Lundqvist C, Laroche C, Kautzner J, Pokushalov E, et al. Contemporary management of patients undergoing atrial fibrillation ablation: in-hospital and 1-year follow-up findings from the ESC-EHRA atrial fibrillation ablation long-term registry. Eur Heart J. 2017;38(17):1303-1316. doi:10.1093/eurheartj/ehw564 · PMID 28104790G3
  10. Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503-3626. doi:10.1093/eurheartj/ehad194 · PMID 37622657G1H3
  11. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. doi:10.1056/NEJMoa043399 · PMID 15659722G2I1
  12. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, Martinez-Alday J, Ruiz-Granell R, Lacunza-Ruiz J, et al. Dual-Chamber Pacing With Closed Loop Stimulation in Recurrent Reflex Vasovagal Syncope: The SPAIN Study. J Am Coll Cardiol. 2017;70(14):1720-1728. doi:10.1016/j.jacc.2017.08.026 · PMID 28958328G2
  13. Barrios V, Escobar C, Prieto L, Osorio G, Polo J, Lobos JM, et al. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study. Rev Esp Cardiol (Engl Ed). 2015;68(9):769-76. doi:10.1016/j.rec.2015.04.017 · PMID 26169326G3
  14. Bassand JP, Accetta G, Camm AJ, Cools F, Fitzmaurice DA, Fox KA, et al. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882-2889. doi:10.1093/eurheartj/ehw233 · PMID 27357359G3
  15. Benezet-Mazuecos J, Rubio JM, Farré J, Quiñones MÁ, Sanchez-Borque P, Macía E. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36(7):830-6. doi:10.1111/pace.12118 · PMID 23510001I1
  16. Benz AP, Olde Nordkamp LRA, McIntyre WF, Dijkshoorn LA, Mondésert B, Bashir J, et al. Inappropriate Shocks From Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: Individual Participant Data Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2026;87(14):1732-1743. doi:10.1016/j.jacc.2025.10.020 · PMID 41369620C5
  17. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. 2020;22(4):515-549. doi:10.1093/europace/euz246 · PMID 31702000C9D4
  18. Boehmer AA, Eckardt L, Rothe M, Kaess BM, Doldi F, Guener F, et al. Pacemaker-implantation and atrioventricular-node ablation vs pulmonary vein isolation for elderly patients with persistent atrial fibrillation: the ABLATE versus PACE trial. Eur Heart J. 2026;pii: ehag742. doi: 10.1093/eurheartj/ehag742. doi:10.1093/eurheartj/ehag742 · PMID 42671117G2
  19. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med. 1997;126(8):621-5. doi:10.7326/0003-4819-126-8-199704150-00006 · PMID 9103129I1
  20. Boriani G, Proietti M, Laroche C, Fauchier L, Marin F, Nabauer M, et al. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace. 2019;21(7):1013-1022. doi:10.1093/europace/euz032 · PMID 30904925G3
  21. Brady WJ, Swart G, DeBehnke DJ, Ma OJ, Aufderheide TP. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation. 1999;41(1):47-55. doi:10.1016/s0300-9572(99)00032-5 · PMID 10459592I1
  22. Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, et al. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation. 2012;125(21):2566-71. doi:10.1161/CIRCULATIONAHA.111.082313 · PMID 22565936G2
  23. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037 · PMID 29562304B6D1G1
  24. Brignole M, Pentimalli F, Palmisano P, Landolina M, Quartieri F, Occhetta E, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021;42(46):4731-4739. doi:10.1093/eurheartj/ehab569 · PMID 34453840G2
  25. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-50. doi:10.1056/NEJMoa032423 · PMID 15152059G2
  26. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720. doi:10.1093/eurheartj/ehz467 · PMID 31504425B6D1G1H1I1
  27. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D'Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace. 2021;23(7):983-1008. doi:10.1093/europace/euaa367 · PMID 33878762C9D4
  28. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2019;40(23):1850-1858. doi:10.1093/eurheartj/ehz103 · PMID 30915475H3
  29. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376(17):1627-1636. doi:10.1056/NEJMoa1701005 · PMID 28317415I1
  30. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57(3):313-21. doi:10.1016/j.jacc.2010.07.046 · PMID 21232669I1
  31. Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513-1524. doi:10.1056/NEJMoa1708454 · PMID 28844193C6G2I1
  32. Cappato R, Castelvecchio S, Ricci C, Bianco E, Vitali-Serdoz L, Gnecchi-Ruscone T, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol. 2012;60(15):1323-9. doi:10.1016/j.jacc.2012.06.031 · PMID 22981555I1
  33. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014;35(47):3346-55. doi:10.1093/eurheartj/ehu367 · PMID 25182247I1
  34. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-12. doi:10.1056/NEJM198908103210629 · PMID 2473403C5G2I1
  35. Casteigt B, Vela E, Valles E, González-Matos CE, Jimenez Lopez J, Falzone PV, et al. Epidemiology, economic burden and mortality of atrial fibrillation in a region with very high life expectancy: a contemporary, population-based analysis in Catalonia. Open Heart. 2026;13(1). doi:10.1136/openhrt-2026-004007 · PMID 41997616H2
  36. Cemin R, Colivicchi F, Maggioni AP, Boriani G, De Luca L, Di Lenarda A, et al. One-year clinical events and management of patients with atrial fibrillation hospitalized in cardiology centers: Data from the BLITZ-AF study. Eur J Intern Med. 2020;74:55-60. doi:10.1016/j.ejim.2019.12.006 · PMID 31952984G3
  37. Chen X, Liu X, Li R, Wang Z, Liang Y, Zhang L, et al. Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial. JAMA Cardiol. 2026;11(4):352-359. doi:10.1001/jamacardio.2026.0083 · PMID 41811342C5G2
  38. Cho MS, Kang DY, Ahn JM, Yun SC, Oh YS, Lee CH, et al. Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med. 2024;391(22):2075-2086. doi:10.1056/NEJMoa2407362 · PMID 39225258C6G2
  39. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF, et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol. 2012;60(20):2092-9. doi:10.1016/j.jacc.2012.07.046 · PMID 23083782I1
  40. Chow CLD, Wong C, Sutherland N, Obeyesekere MN, Wong GR, Eastwood CM, et al. Clinical Outcomes of Conduction System Pacing vs Right Ventricular Septal Pacing in Atrioventricular Block: The CSPACE Randomized Controlled Trial. J Am Coll Cardiol. 2025;86(8):563-573. doi:10.1016/j.jacc.2025.06.043 · PMID 40835365C5
  41. Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17-e91. doi:10.1016/j.hrthm.2023.03.1538 · PMID 37283271G1
  42. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-49. doi:10.1056/NEJMoa050496 · PMID 15753115G2
  43. Coll-Vinent B, Martín A, Malagón F, Suero C, Sánchez J, Varona M, et al. Stroke prophylaxis in atrial fibrillation: searching for management improvement opportunities in the emergency department: the HERMES-AF study. Ann Emerg Med. 2015;65(1):1-12. doi:10.1016/j.annemergmed.2014.07.016 · PMID 25182543G3
  44. Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F, et al. Benefits of Emergency Departments' Contribution to Stroke Prophylaxis in Atrial Fibrillation: The EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation). Stroke. 2017;48(5):1344-1352. doi:10.1161/STROKEAHA.116.014855 · PMID 28389612G3
  45. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023;402(10413):1627-1635. doi:10.1016/S0140-6736(23)01689-6 · PMID 37640035C6
  46. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342(19):1385-91. doi:10.1056/NEJM200005113421902 · PMID 10805823G2
  47. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-71. doi:10.1001/jama.295.2.165 · PMID 16403928I1
  48. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. doi:10.1056/NEJMoa0905561 · PMID 19717844C5G2I1
  49. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268-76. doi:10.1056/NEJMoa1109867 · PMID 22082198C5G2I1
  50. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806-17. doi:10.1056/NEJMoa1007432 · PMID 21309657G2I1
  51. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022;387(11):978-988. doi:10.1056/NEJMoa2209051 · PMID 36036525C5I1
  52. Correction to: 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2026;47(38):5557. doi:10.1093/eurheartj/ehag645 · PMID 42605809G1
  53. Cosío FG. Atrial Flutter, Typical and Atypical: A Review. Arrhythm Electrophysiol Rev. 2017;6(2):55-62. doi:10.15420/aer.2017.5.2 · PMID 28835836H1
  54. Curila K, Mizner J, Morava J, Smisek R, Vesela J, Sussenbek O, et al. Prospective randomized trial of conduction system pacing vs right ventricular pacing for patients with atrioventricular block; Prague CSP trial. Heart Rhythm. 2025;22(10):e894-e902. doi:10.1016/j.hrthm.2025.05.036 · PMID 40412596C5
  55. Curtis AB, Worley SJ, Adamson PB, Chung ES, Niazi I, Sherfesee L, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368(17):1585-93. doi:10.1056/NEJMoa1210356 · PMID 23614585C5G2
  56. Cózar-León R, García-Fernández FJ, Navarro-Manchón J, Fontenla A, Molina-Lerma M, Calvo D, et al. Spanish pacemaker registry. 23rd official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2025). Rev Esp Cardiol (Engl Ed). 2026;pii: S1885-5857(26)00208-2. doi: 10.1016/j.rec.2026.07.008. doi:10.1016/j.rec.2026.07.008 · PMID 42763016G3H2
  57. Dalmau Llorca MR, Aguilar Martín C, Carrasco-Querol N, Hernández Rojas Z, Forcadell Drago E, Rodríguez Cumplido D, et al. Anticoagulation Control with Acenocoumarol or Warfarin in Non-Valvular Atrial Fibrillation in Primary Care (Fantas-TIC Study). Int J Environ Res Public Health. 2021;18(11). doi:10.3390/ijerph18115700 · PMID 34073370C5I1
  58. de Burgos-Lunar C, Del Cura-González I, Cárdenas-Valladolid J, Gómez-Campelo P, Abánades-Herranz JC, López-de Andrés A, et al. Real-world data in primary care: validation of diagnosis of atrial fibrillation in primary care electronic medical records and estimated prevalence among consulting patients'. BMC Prim Care. 2023;24(1):4. doi:10.1186/s12875-022-01961-y · PMID 36600196H2
  59. De Potter TJR, Valeriano C, Akerstrom F, Cassese S, Finlay M, Gupta D, et al. Vascular access and closure management for electrophysiological interventions in 2025: a Clinical Consensus Statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Surgery. Europace. 2025;27(10). doi:10.1093/europace/euaf115 · PMID 41118456C9D4
  60. De Vriese AS, Caluwé R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. J Am Soc Nephrol. 2021;32(6):1474-1483. doi:10.1681/ASN.2020111566 · PMID 33753537C6
  61. Delaney B, Loy J, Kelly AM. The relative efficacy of adenosine versus verapamil for the treatment of stable paroxysmal supraventricular tachycardia in adults: a meta-analysis. Eur J Emerg Med. 2011;18(3):148-52. doi:10.1097/MEJ.0b013e3283400ba2 · PMID 20926952I1
  62. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia E, et al. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group. Ann Intern Med. 1990;113(2):104-10. doi:10.7326/0003-4819-113-2-104 · PMID 2193560I1
  63. Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. N Engl J Med. 2026;394(21):2083-2094. doi:10.1056/NEJMoa2517213 · PMID 41910347G2
  64. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324(12):781-8. doi:10.1056/NEJM199103213241201 · PMID 1900101I1
  65. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206-14. doi:10.1056/NEJMoa1300615 · PMID 23991661C5I1
  66. Ekanem E, Neuzil P, Reichlin T, Kautzner J, van der Voort P, Jais P, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med. 2024;30(7):2020-2029. doi:10.1038/s41591-024-03114-3 · PMID 38977913G3
  67. El-Chami MF, Bockstedt L, Longacre C, Higuera L, Stromberg K, Crossley G, et al. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J. 2022;43(12):1207-1215. doi:10.1093/eurheartj/ehab767 · PMID 34788416C5
  68. Enge K, Tveit A, Enger S, Onarheim S, Pripp AH, Rønningen PS, et al. Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2024;10(6):515-525. doi:10.1093/ehjcvp/pvae032 · PMID 38702844I1
  69. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, Roldán V, Muñiz J, Raña-Míguez P, et al. Quality of oral anticoagulation with vitamin K antagonists in 'real-world' patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018;20(9):1435-1441. doi:10.1093/europace/eux314 · PMID 29095971G3
  70. Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, et al. Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39(32):2959-2971. doi:10.1093/eurheartj/ehy148 · PMID 29659797I1
  71. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33(2):304-10. doi:10.1016/s0735-1097(98)00561-0 · PMID 9973007I1
  72. Ferrick AM, Raj SR, Deneke T, Kojodjojo P, Lopez-Cabanillas N, Abe H, et al. 2023 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Practical Management of the Remote Device Clinic. Europace. 2023;25(5). doi:10.1093/europace/euad123 · PMID 37208301C9
  73. Flyer JN, Zuckerman WA, Richmond ME, Anderson BR, Mendelsberg TG, McAllister JM, et al. Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation. Circulation. 2017;135(25):2485-2493. doi:10.1161/CIRCULATIONAHA.117.028087 · PMID 28450351I1
  74. Frodi DM, Boveda S, Fournier V, Kerkouri F, Anselme F, Deharo JC, et al. Temporal trends in population characteristics and type of device among primary prevention implantable cardioverter defibrillator recipients: The DAI-PP programme. Arch Cardiovasc Dis. 2025;118(3):178-184. doi:10.1016/j.acvd.2024.10.335 · PMID 39890483G3
  75. Funck RC, Müller HH, Lunati M, De Roy L, Klein N, Meisel E, et al. Biventricular vs. right ventricular pacing devices in patients anticipated to require frequent ventricular pacing (BioPace). Europace. 2025;27(3). doi:10.1093/europace/euaf029 · PMID 40105785C5
  76. Gao D, Van Herendael H, Alshengeiti L, Dorian P, Mangat I, Korley V, et al. Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator. J Cardiovasc Pharmacol. 2013;62(2):199-204. doi:10.1097/FJC.0b013e31829651fe · PMID 23609328I1
  77. Gaudino M, Sanna T, Ballman KV, Robinson NB, Hameed I, Audisio K, et al. Posterior left pericardiotomy for the prevention of atrial fibrillation after cardiac surgery: an adaptive, single-centre, single-blind, randomised, controlled trial. Lancet. 2021;398(10316):2075-2083. doi:10.1016/S0140-6736(21)02490-9 · PMID 34788640C6
  78. Gaztañaga L, Marchlinski FE, Betensky BP. Mechanisms of cardiac arrhythmias. Rev Esp Cardiol (Engl Ed). 2012;65(2):174-85. doi:10.1016/j.recesp.2011.09.018 · PMID 22192903H1
  79. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016;375(25):2423-2434. doi:10.1056/NEJMoa1611594 · PMID 27959713C6G2I1
  80. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. doi:10.1056/NEJMoa1310907 · PMID 24251359C5G2I1
  81. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-3520. doi:10.1093/eurheartj/ehab364 · PMID 34455430B6C9D1D4G1H1I1
  82. Glikson M, Burri H, Abdin A, Cano O, Curila K, De Pooter J, et al. European Society of Cardiology (ESC) clinical consensus statement on indications for conduction system pacing, with special contribution of the European Heart Rhythm Association of the ESC and endorsed by the Asia Pacific Heart Rhythm Society, the Canadian Heart Rhythm Society, the Heart Rhythm Society, and the Latin American Heart Rhythm Society. Europace. 2025;27(4). doi:10.1093/europace/euaf050 · PMID 40159278C5G1
  83. Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet. 2016;388(10055):1995-2003. doi:10.1016/S0140-6736(16)31474-X · PMID 27590218I1
  84. Goette A, Corradi D, Dobrev D, Aguinaga L, Cabrera JA, Chugh SS, et al. Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024;26(9). doi:10.1093/europace/euae204 · PMID 39077825H1
  85. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. doi:10.1056/NEJMoa1107039 · PMID 21870978C5G2I1
  86. Gulizia MM, Cemin R, Colivicchi F, De Luca L, Di Lenarda A, Boriani G, et al. Management of atrial fibrillation in the emergency room and in the cardiology ward: the BLITZ AF study. Europace. 2019;21(2):230-238. doi:10.1093/europace/euy166 · PMID 30060174G3
  87. Gómez-Doblas JJ, Muñiz J, Martin JJ, Rodríguez-Roca G, Lobos JM, Awamleh P, et al. Prevalence of atrial fibrillation in Spain. OFRECE study results. Rev Esp Cardiol (Engl Ed). 2014;67(4):259-69. doi:10.1016/j.rec.2013.07.014 · PMID 24774588H2
  88. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67. doi:10.7326/0003-4819-146-12-200706190-00007 · PMID 17577005C5I1
  89. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66. doi:10.1056/NEJM199809033391003 · PMID 9725923H1
  90. Healey JS, Krahn AD, Bashir J, Amit G, Philippon F, McIntyre WF, et al. Perioperative Safety and Early Patient and Device Outcomes Among Subcutaneous Versus Transvenous Implantable Cardioverter Defibrillator Implantations : A Randomized, Multicenter Trial. Ann Intern Med. 2022;175(12):1658-1665. doi:10.7326/M22-1566 · PMID 36343346C5
  91. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. N Engl J Med. 2024;390(2):107-117. doi:10.1056/NEJMoa2310234 · PMID 37952132G2I1
  92. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, et al. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur Heart J. 2012;33(21):2692-9. doi:10.1093/eurheartj/ehs071 · PMID 22453654D4
  93. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351(24):2481-8. doi:10.1056/NEJMoa041489 · PMID 15590950G2
  94. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-78. doi:10.1056/NEJMoa0803778 · PMID 19213680C5G2I1
  95. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-42. doi:10.1016/S0140-6736(09)61343-X · PMID 19683639G2
  96. Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12. doi:10.1016/j.jacc.2014.04.029 · PMID 24998121G2
  97. Jais P, Neuzil P, Scherr D, Frison E, Knecht S, Boveda S, et al. Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROX-AF trial. Eur Heart J. 2026;47(13):1527-1537. doi:10.1093/eurheartj/ehaf1115 · PMID 41568658C5
  98. Jiménez-Candil J, González VB, Rueda EA, Asensi JO, Calvo D. Spanish implantable cardioverter-defibrillator registry. 22nd official report of the Heart Rhythm Association of the Spanish Society of Cardiology (2025). Rev Esp Cardiol (Engl Ed). 2026;pii: S1885-5857(26)00209-4. doi: 10.1016/j.rec.2026.06.019. doi:10.1016/j.rec.2026.06.019 · PMID 42763015G3H2
  99. Joglar JA, Kapa S, Saarel EV, Dubin AM, Gorenek B, Hameed AB, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm. 2023;20(10):e175-e264. doi:10.1016/j.hrthm.2023.05.017 · PMID 37211147G1
  100. Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(1):e1-e156. doi:10.1161/CIR.0000000000001193 · PMID 38033089G1
  101. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. 2024;149(4):279-289. doi:10.1161/CIRCULATIONAHA.123.066485 · PMID 37634130C5C6G2I1
  102. Jøns C, Zheng C, Winsløw UCG, Danielsen EM, Sakthivel T, Frandsen EA, et al. Increasing the Potassium Level in Patients at High Risk for Ventricular Arrhythmias. N Engl J Med. 2025;393(20):1979-1989. doi:10.1056/NEJMoa2509542 · PMID 40879429G2
  103. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol. 2017;2(7):759-766. doi:10.1001/jamacardio.2017.1320 · PMID 28492868I1
  104. Karakasis P, Vlachos K, Siontis KC, Cano Ó, Tzeis S, Strik M, et al. Conduction system vs. biventricular pacing in heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials. Europace. 2026;28(8). doi:10.1093/europace/euag170 · PMID 42586561C5
  105. Kim D, Shim J, Choi EK, Oh IY, Kim J, Lee YS, et al. Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial. JAMA. 2025;334(14):1246-1254. doi:10.1001/jama.2025.14679 · PMID 40886309G2
  106. Kim D, Lee YS, Shim J, Yu HT, Park J, Park JK, et al. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk. N Engl J Med. 2026;395(12):1155-1165. doi:10.1056/NEJMoa2607978 · PMID 42663303G2
  107. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380(9838):238-46. doi:10.1016/S0140-6736(12)60570-4 · PMID 22713626I1
  108. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-1316. doi:10.1056/NEJMoa2019422 · PMID 32865375G2
  109. Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes. N Engl J Med. 2023;389(13):1167-1179. doi:10.1056/NEJMoa2303062 · PMID 37622677G2I1
  110. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or Transvenous Defibrillator Therapy. N Engl J Med. 2020;383(6):526-536. doi:10.1056/NEJMoa1915932 · PMID 32757521C5G2
  111. Knops RE, Pepplinkhuizen S, Delnoy PPHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Device-related complications in subcutaneous versus transvenous ICD: a secondary analysis of the PRAETORIAN trial. Eur Heart J. 2022;43(47):4872-4883. doi:10.1093/eurheartj/ehac496 · PMID 36030464C5
  112. Knops RE, Marquie C, Nordbeck P, Tilz RR, Dijkshoorn LA, Quast ABE, et al. Subcutaneous Defibrillator Implantation With or Without Defibrillation Test: The Primary Results of the Randomized PRAETORIAN-DFT Trial. Circulation. 2026;154(6):520-531. doi:10.1161/CIRCULATIONAHA.126.080638 · PMID 42033346G2
  113. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-43. doi:10.1016/S0140-6736(14)61373-8 · PMID 25193873I1
  114. Kotecha D, Bunting KV, Gill SK, Mehta S, Stanbury M, Jones JC, et al. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020;324(24):2497-2508. doi:10.1001/jama.2020.23138 · PMID 33351042C5G2I1
  115. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2(6):652-9. doi:10.1161/CIRCEP.109.870204 · PMID 19948506I1
  116. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102(7):748-54. doi:10.1161/01.cir.102.7.748 · PMID 10942742I1
  117. Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016;374(23):2235-45. doi:10.1056/NEJMoa1602014 · PMID 27042964C5
  118. Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341(12):871-8. doi:10.1056/NEJM199909163411203 · PMID 10486418I1
  119. Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2016;374(18):1711-22. doi:10.1056/NEJMoa1514204 · PMID 27043165I1
  120. Kumbhani DJ, Armbruster AL, Cheng RK, Chrispin J, Fischer U, Holbrook AM, et al. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026;88(11):1255-1283. doi:10.1016/j.jacc.2026.05.033 · PMID 42377292G1
  121. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382-e482. doi:10.1161/CIR.0000000000000628 · PMID 30586772G1
  122. Kusumoto FM, Schoenfeld MH, Barrett C, Edgerton JR, Ellenbogen KA, Gold MR, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044 · PMID 30412709I1
  123. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-87. doi:10.1056/NEJMoa0800456 · PMID 18565860C5I1
  124. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. doi:10.1056/NEJMoa1608029 · PMID 27571011G2
  125. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346(24):1854-62. doi:10.1056/NEJMoa013040 · PMID 12063369G2
  126. Landmesser U, Skurk C, Kirchhof P, Lewalter T, Hartung J, Rroku A, et al. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. N Engl J Med. 2026;394(13):1270-1280. doi:10.1056/NEJMoa2513310 · PMID 41849741G2
  127. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597-605. doi:10.1111/j.1540-8167.2010.01764.x · PMID 20384650I1
  128. Lei M, Wu L, Terrar DA, Huang CL. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018;138(17):1879-1896. doi:10.1161/CIRCULATIONAHA.118.035455 · PMID 30354657H1
  129. Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation. N Engl J Med. 2025;393(16):1578-1588. doi:10.1056/NEJMoa2507532 · PMID 40888725G2
  130. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509-1524. doi:10.1056/NEJMoa1817083 · PMID 30883055C6G2I1
  131. Lopes RD, Atlas SJ, Go AS, Lubitz SA, McManus DD, Dolor RJ, et al. Effect of Screening for Undiagnosed Atrial Fibrillation on Stroke Prevention. J Am Coll Cardiol. 2024;84(21):2073-2084. doi:10.1016/j.jacc.2024.08.019 · PMID 39230544G2
  132. Lévy S, Hartikainen J, Ritz B, Juhlin T, Carbajosa-Dalmau J, Domanovits H. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study. Cardiovasc Drugs Ther. 2021;35(2):283-292. doi:10.1007/s10557-020-07103-9 · PMID 33206300I1
  133. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503. doi:10.1016/S0140-6736(07)61233-1 · PMID 17693178I1
  134. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31(7):806-14. doi:10.1093/eurheartj/ehq025 · PMID 20172912H3
  135. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-427. doi:10.1056/NEJMoa1707855 · PMID 29385358G2
  136. Martino A, Rebecchi M, Sette A, Cicogna F, Politano A, Sgueglia M, et al. Ivabradine versus bisoprolol in the treatment of inappropriate sinus tachycardia: a long-term follow-up study. J Cardiovasc Med (Hagerstown). 2021;22(11):892-900. doi:10.2459/JCM.0000000000001203 · PMID 34747925I1
  137. Martín A, Coll-Vinent B, Suero C, Fernández-Simón A, Sánchez J, Varona M, et al. Benefits of Rhythm Control and Rate Control in Recent-onset Atrial Fibrillation: The HERMES-AF Study. Acad Emerg Med. 2019;26(9):1034-1043. doi:10.1111/acem.13703 · PMID 30703274G3
  138. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N Engl J Med. 1993;329(7):452-8. doi:10.1056/NEJM199308123290702 · PMID 8332150I1
  139. Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018;15(2):240-247. doi:10.1016/j.hrthm.2017.10.004 · PMID 29017929I1
  140. Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M, et al. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3. J Am Coll Cardiol. 2016;67(9):1053-1058. doi:10.1016/j.jacc.2015.12.033 · PMID 26940925I1
  141. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, et al. Interplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT Syndrome. J Am Coll Cardiol. 2018;71(15):1663-1671. doi:10.1016/j.jacc.2018.01.078 · PMID 29650123H3
  142. Merino JL, Tamargo J, Blomström-Lundqvist C, Boriani G, Crijns HJGM, Dobrev D, et al. Practical compendium of antiarrhythmic drugs: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology. Europace. 2025;27(8). doi:10.1093/europace/euaf076 · PMID 40159403G1
  143. Monteiro P, em nome dos investigadores do estudo Safira. The SAFIRA study: A reflection on the prevalence and treatment patterns of atrial fibrillation and cardiovascular risk factors in 7500 elderly subjects. Rev Port Cardiol (Engl Ed). 2018;37(4):307-313. doi:10.1016/j.repc.2017.08.006 · PMID 29703518G3
  144. Morentin B, Suárez-Mier MP, Monzó A, Ballesteros J, Molina P, Lucena J. Sports-related sudden cardiac death in Spain. A multicenter, population-based, forensic study of 288 cases. Rev Esp Cardiol (Engl Ed). 2021;74(3):225-232. doi:10.1016/j.rec.2020.05.044 · PMID 32920001H2
  145. Morin DP, Kaufman ES, Campbell KB, Epstein AE, Goldberger ZD, Görenek B, et al. 2026 HRS/PACES scientific statement on the use of antiarrhythmic drugs in understudied clinical scenarios. Heart Rhythm. 2026;pii: S1547-5271(26)02580-4. doi: 10.1016/j.hrthm.2026.07.012. doi:10.1016/j.hrthm.2026.07.012 · PMID 42695957G1
  146. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877-83. doi:10.1056/NEJMoa013474 · PMID 11907286G2
  147. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361(14):1329-38. doi:10.1056/NEJMoa0906431 · PMID 19723701G2
  148. Nattel S, Heijman J, Zhou L, Dobrev D. Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. Circ Res. 2020;127(1):51-72. doi:10.1161/CIRCRESAHA.120.316363 · PMID 32717172H1
  149. Nielsen JC, Thomsen PE, Højberg S, Møller M, Vesterlund T, Dalsgaard D, et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. Eur Heart J. 2011;32(6):686-96. doi:10.1093/eurheartj/ehr022 · PMID 21300730G2
  150. Nielsen JC, Svendsen JH, Johansen JB, Larsen JM, Larroudé CE, Poulsen SH, et al. Targeted left ventricular lead placement in biventricular pacing for heart failure: a national, multicentre, double-blind, randomised controlled trial in Denmark. Lancet. 2026;408(10561):1175-1185. doi:10.1016/S0140-6736(26)01597-7 · PMID 42673980G2
  151. O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. doi:10.1093/eurheartj/eht439 · PMID 24126876H3
  152. Okumura K, Akao M, Yoshida T, Kawata M, Okazaki O, Akashi S, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med. 2020;383(18):1735-1745. doi:10.1056/NEJMoa2012883 · PMID 32865374C6G2I1
  153. Olde Nordkamp LRA, de Veld JA, Ghani A, Kuschyk J, Bonnemeier H, Bode K, et al. Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial. Circulation. 2025;152(3):172-182. doi:10.1161/CIRCULATIONAHA.125.074576 · PMID 40279654C5
  154. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable Cardioverter-Defibrillator after Myocardial Infarction. N Engl J Med. 2018;379(13):1205-1215. doi:10.1056/NEJMoa1800781 · PMID 30280654G2
  155. Olshansky B, Rosenfeld LE, Warner AL, Solomon AJ, O'Neill G, Sharma A, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43(7):1201-8. doi:10.1016/j.jacc.2003.11.032 · PMID 15063430I1
  156. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al. Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study. Eur Heart J. 2017;38(17):1329-1335. doi:10.1093/eurheartj/ehw230 · PMID 27354046I1
  157. Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2020;75(25):3122-3135. doi:10.1016/j.jacc.2020.04.067 · PMID 32586585G2
  158. Osmancik P, Roubicek T, Havranek S, Chovancik J, Bulkova V, Herman D, et al. Catheter Ablation vs Lifestyle Modification With Antiarrhythmic Drugs to Treat Atrial Fibrillation: PRAGUE-25 Trial. J Am Coll Cardiol. 2025;86(1):18-28. doi:10.1016/j.jacc.2025.04.042 · PMID 40602939G2
  159. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1261-1274. doi:10.1001/jama.2019.0693 · PMID 30874766G2
  160. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2016;133(14):e506-74. doi:10.1161/CIR.0000000000000311 · PMID 26399663G1
  161. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. doi:10.1056/NEJMoa1009638 · PMID 21830957C5G2I1
  162. Paul Nordin A, Charitakis E, Carnlöf C, Åkerström F, Saluveer O, Almroth H, et al. Low-Voltage Ablation in Persistent Atrial Fibrillation: The IDEAL-AF Randomized Clinical Trial. JAMA. 2026;doi: 10.1001/jama.2026.17274. doi:10.1001/jama.2026.17274 · PMID 42669133G2
  163. Peretto G, Basso C, Berruezo A, Bollano E, Caforio ALP, Casella M, et al. Workup and management of rhythm disorders in myocarditis and inflammatory cardiomyopathy: a clinical consensus statement of the European Heart Rhythm Association and the Heart Failure Association of the ESC, the ESC Working Group on Myocardial & Pericardial Diseases, the European Association of Preventive Cardiology of the ESC, the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society. Eur J Heart Fail. 2026;pii: xuag271. doi: 10.1093/ejhf/xuag271. doi:10.1093/ejhf/xuag271 · PMID 42663246G1
  164. Perrett M, Gohil N, Tica O, Bunting KV, Kotecha D. Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clin Res Cardiol. 2024;113(6):831-841. doi:10.1007/s00392-023-02295-0 · PMID 37658166I1
  165. Piccini JP, El-Chami M, Wherry K, Crossley GH, Kowal RC, Stromberg K, et al. Contemporaneous Comparison of Outcomes Among Patients Implanted With a Leadless vs Transvenous Single-Chamber Ventricular Pacemaker. JAMA Cardiol. 2021;6(10):1187-1195. doi:10.1001/jamacardio.2021.2621 · PMID 34319383C5
  166. Piccini JP, Patel MR, Steffel J, Ferdinand K, Van Gelder IC, Russo AM, et al. Asundexian versus Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392(1):23-32. doi:10.1056/NEJMoa2407105 · PMID 39225267G2
  167. Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022;146(23):1735-1745. doi:10.1161/CIRCULATIONAHA.121.054990 · PMID 36335914C6
  168. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707278 · PMID 28693366I1
  169. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010;106(9):1277-83. doi:10.1016/j.amjcard.2010.06.054 · PMID 21029824I1
  170. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Cygankiewicz I, Wranicz JK. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther. 2013;18(4):338-44. doi:10.1177/1074248413478172 · PMID 23426376I1
  171. Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013;15(1):116-21. doi:10.1093/europace/eus204 · PMID 22772053I1
  172. Pérez Cabeza AI, Rivera-Caravaca JM, Roldán-Rabadán I, García Seara J, Bertomeu-Gonzalez V, Leal M, et al. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry. Eur J Clin Invest. 2022;52(4):e13709. doi:10.1111/eci.13709 · PMID 34757635G3
  173. Raviele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L, et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace. 2011;13(7):920-34. doi:10.1093/europace/eur130 · PMID 21697315C7
  174. Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, et al. Percutaneous Implantation of an Entirely Intracardiac Leadless Pacemaker. N Engl J Med. 2015;373(12):1125-35. doi:10.1056/NEJMoa1507192 · PMID 26321198G2
  175. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023;389(18):1660-1671. doi:10.1056/NEJMoa2307291 · PMID 37634148C5G2
  176. Reichlin T, Kueffer T, Badertscher P, Jüni P, Knecht S, Thalmann G, et al. Pulsed Field or Cryoballoon Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2025;392(15):1497-1507. doi:10.1056/NEJMoa2502280 · PMID 40162734C5G2
  177. Reinecke H, Engelbertz C, Bauersachs R, Breithardt G, Echterhoff HH, Gerß J, et al. A Randomized Controlled Trial Comparing Apixaban With the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study. Circulation. 2023;147(4):296-309. doi:10.1161/CIRCULATIONAHA.122.062779 · PMID 36335915C6
  178. Rivard L, Khairy P, Talajic M, Tardif JC, Healey JS, Black SE, et al. Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial. Nat Med. 2026;32(1):297-305. doi:10.1038/s41591-025-04101-y · PMID 41501492G2
  179. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013-22. doi:10.1056/NEJMra032426 · PMID 14999113H1
  180. Rodríguez-García J, Ramos R, Blanch J, Ponjoan A, Dallaglio PD, San Antonio R, et al. Recent trends and future projections of atrial fibrillation epidemiology in a large european population. Eur J Intern Med. 2026;145:106683. doi:10.1016/j.ejim.2025.106683 · PMID 41456979H2
  181. Rosell-Ortiz F, Escalada-Roig X, Fernández Del Valle P, Sánchez-Santos L, Navalpotro-Pascual JM, Echarri-Sucunza A, et al. Out-of-hospital cardiac arrest (OHCA) attended by mobile emergency teams with a physician on board. Results of the Spanish OHCA Registry (OSHCAR). Resuscitation. 2017;113:90-95. doi:10.1016/j.resuscitation.2017.01.029 · PMID 28202420G3
  182. Roten L, Maurhofer J, Krisai P, Breitenstein A, Koepfli P, Saguner AM, et al. Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial. JAMA. 2026;doi: 10.1001/jama.2026.17598. doi:10.1001/jama.2026.17598 · PMID 42667231G2
  183. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342(13):913-20. doi:10.1056/NEJM200003303421302 · PMID 10738049C5I1
  184. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117(12):1518-25. doi:10.1161/CIRCULATIONAHA.107.723866 · PMID 18332267I1
  185. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77. doi:10.1056/NEJMoa0708789 · PMID 18565859G2
  186. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62. doi:10.1016/S0140-6736(13)62343-0 · PMID 24315724C5I1
  187. Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, et al. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. N Engl J Med. 2025;392(4):361-371. doi:10.1056/NEJMoa2406674 · PMID 39842011G2
  188. Ruiz Azpiazu JI, Fernández Del Valle P, Escriche MC, Royo Embid S, Fernández Barreras C, Azeli Y, et al. Incidence, treatment, and factors associated with survival of out-of-hospital cardiac arrest attended by Spanish emergency services: report from the Out-of-Hospital Spanish Cardiac Arrest Registry for 2022. Emergencias. 2024;36(2):131-139. doi:10.55633/s3me/014.2024 · PMID 38597620G3H2
  189. Ruiz Ortiz M, Muñiz J, Raña Míguez P, Roldán I, Marín F, Asunción Esteve-Pastor M, et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry. Europace. 2018;20(10):1577-1583. doi:10.1093/europace/eux316 · PMID 29186393G3
  190. Ruiz Ortiz M, Arbelo E, Roldán Rabadán I, Marín F, Pérez Cabeza A, Marzoa Rivas R, et al. The European Society of Cardiology quality indicators in atrial fibrillation in centers of excellence in Spain: the SEC-EXCELENTE FA registry. Rev Esp Cardiol (Engl Ed). 2025;78(5):389-400. doi:10.1016/j.rec.2024.08.007 · PMID 39303807G3
  191. Ruiz-Azpiazu JI, Daponte-Codina A, Fernández Del Valle P, López-Cabeza N, Jiménez-Fàbrega FX, Iglesias-Vázquez JA, et al. Regional variation in the incidence, general characteristics, and outcomes of prehospital cardiac arrest in Spain: the Out-of-Hospital Spanish Cardiac Arrest Registry. Emergencias. 2021;33(1):15-22. PMID 33496395G3
  192. Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369(15):1395-405. doi:10.1056/NEJMoa1306687 · PMID 23998714G2
  193. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin JF, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med. 2016;375(2):111-21. doi:10.1056/NEJMoa1513614 · PMID 27149033I1
  194. Sarquella-Brugada G, Mazzanti A, Baban A, Campuzano O, Conte G, Crotti L, et al. Diagnosis and management of very rare primary arrhythmia syndromes in children and adults: a Clinical Consensus Statement of the European Heart Rhythm Association of the ESC and the Association of Cardiovascular Nursing & Allied Professions of the ESC, endorsed by the Association for European Paediatric and Congenital Cardiology. Europace. 2026;28(8). doi:10.1093/europace/euag184 · PMID 42669047G1
  195. Scherr D, Frausing MHJP, Maciejewski C, Barisone M, Boriani G, Breitenstein A, et al. Same-day discharge after electrophysiological and cardiac implantable electronic device procedures: a clinical consensus statement of the European Heart Rhythm Association (EHRA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC. Europace. 2026;28(4). doi:10.1093/europace/euag065 · PMID 41973847C9D4
  196. Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, Vermeer SE, Kerkhoff H, Zock E, et al. Apixaban versus no anticoagulation after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol. 2021;20(11):907-916. doi:10.1016/S1474-4422(21)00298-2 · PMID 34687635C6
  197. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92(12):3381-6. doi:10.1161/01.cir.92.12.3381 · PMID 8521555I1
  198. Shen WK, Sheldon RS, Benditt DG, Cohen MI, Forman DE, Goldberger ZD, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136(5):e60-e122. doi:10.1161/CIR.0000000000000499 · PMID 28280231G1
  199. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861-72. doi:10.1056/NEJMoa041705 · PMID 15872201C5I1
  200. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987-99. doi:10.1056/NEJMoa054686 · PMID 17804843I1
  201. Soar J, Böttiger BW, Carli P, Jiménez FC, Cimpoesu D, Cole G, et al. European Resuscitation Council Guidelines 2025 Adult Advanced Life Support. Resuscitation. 2025;215 Suppl 1:110769. doi:10.1016/j.resuscitation.2025.110769 · PMID 41117572I1
  202. Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, et al. Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation. N Engl J Med. 2023;389(15):1380-1389. doi:10.1056/NEJMoa2306037 · PMID 37634135G2
  203. SoSTART Collaboration. Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial. Lancet Neurol. 2021;20(10):842-853. doi:10.1016/S1474-4422(21)00264-7 · PMID 34487722C6
  204. Sotomi Y, Kozuma K, Higuchi Y, Nakazawa G, Morino Y, Ando K, et al. 1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial. Lancet. 2026;408(10553):440-452. doi:10.1016/S0140-6736(26)00665-3 · PMID 42456692G2
  205. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065 · PMID 33895845D4G1
  206. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361(15):1427-36. doi:10.1056/NEJMoa0901889 · PMID 19812399G2
  207. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5):488-94. doi:10.1161/CIRCULATIONAHA.114.011777 · PMID 25499873G3
  208. Svendsen JH, Diederichsen SZ, Højberg S, Krieger DW, Graff C, Kronborg C, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310):1507-1516. doi:10.1016/S0140-6736(21)01698-6 · PMID 34469766G2
  209. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498-1506. doi:10.1016/S0140-6736(21)01637-8 · PMID 34469764G2
  210. Swart G, Brady WJ Jr, DeBehnke DJ, MA OJ, Aufderheide TP. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg Med. 1999;17(7):647-52. doi:10.1016/s0735-6757(99)90151-1 · PMID 10597081I1
  211. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363(25):2385-95. doi:10.1056/NEJMoa1009540 · PMID 21073365G2
  212. Taub PR, Zadourian A, Lo HC, Ormiston CK, Golshan S, Hsu JC. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861-871. doi:10.1016/j.jacc.2020.12.029 · PMID 33602468I1
  213. Toff WD, Camm AJ, Skehan JD, United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block. N Engl J Med. 2005;353(2):145-55. doi:10.1056/NEJMoa042283 · PMID 16014884G2
  214. Tse G. Mechanisms of cardiac arrhythmias. J Arrhythm. 2016;32(2):75-81. doi:10.1016/j.joa.2015.11.003 · PMID 27092186H1
  215. Tsuji Y, Yamazaki M, Shimojo M, Yanagisawa S, Inden Y, Murohara T. Mechanisms of torsades de pointes: an update. Front Cardiovasc Med. 2024;11:1363848. doi:10.3389/fcvm.2024.1363848 · PMID 38504714H1
  216. Tzeis S, Gerstenfeld EP, Kalman J, Saad EB, Sepehri Shamloo A, Andrade JG, et al. 2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4). doi:10.1093/europace/euae043 · PMID 38587017C5C9D4G1
  217. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, et al. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013;111(2):225-30. doi:10.1016/j.amjcard.2012.09.020 · PMID 23111138C5I1
  218. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, et al. Calcium channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J. 2014;35(8):517-24. doi:10.1093/eurheartj/eht429 · PMID 24135831I1
  219. Valembois L, Audureau E, Takeda A, Jarzebowski W, Belmin J, Lafuente-Lafuente C. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049. doi:10.1002/14651858.CD005049.pub5 · PMID 31483500C5I1
  220. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834-40. doi:10.1056/NEJMoa021375 · PMID 12466507G2
  221. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362(15):1363-73. doi:10.1056/NEJMoa1001337 · PMID 20231232G2
  222. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176 · PMID 39210723B6C9D1D3D4G1H1I1
  223. Verma A, Birnie DH, Jiang C, Heidbüchel H, Hindricks G, Kirchhof P, et al. Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation. N Engl J Med. 2026;394(4):323-332. doi:10.1056/NEJMoa2509688 · PMID 41211931G2
  224. Verma A, Hocini M, Andrade J, Gerstenfeld E, Kapa S, Lakkireddy D, et al. 2026 HRS/EHRA scientific statement on pulsed field ablation for cardiac arrhythmias. Heart Rhythm. 2026;23(9):e2195-e2234. doi:10.1016/j.hrthm.2026.02.006 · PMID 41690439G1
  225. Vogler J, Breithardt G, Eckardt L. Bradyarrhythmias and conduction blocks. Rev Esp Cardiol (Engl Ed). 2012;65(7):656-67. doi:10.1016/j.recesp.2012.01.025 · PMID 22627074H1
  226. Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335-1343. doi:10.1016/S0140-6736(19)31872-0 · PMID 31492505C6G2I1
  227. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348(9019):7-12. doi:10.1016/s0140-6736(96)02149-6 · PMID 8691967I1
  228. Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, et al. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022;80(13):1205-1216. doi:10.1016/j.jacc.2022.07.019 · PMID 36137670G2
  229. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Durrani S, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2021;384(4):316-324. doi:10.1056/NEJMoa2029554 · PMID 33197158G2
  230. Wazni OM, Saliba WI, Nair DG, Marijon E, Schmidt B, Hounshell T, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. N Engl J Med. 2025;392(13):1277-1287. doi:10.1056/NEJMoa2408308 · PMID 39555822G2
  231. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. N Engl J Med. 2021;384(22):2081-2091. doi:10.1056/NEJMoa2101897 · PMID 33999547C6G2
  232. Wigginton JG, Agarwal S, Bartos JA, Coute RA, Drennan IR, Haamid A, et al. Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2025;152(16_suppl_2):S538-S577. doi:10.1161/CIR.0000000000001376 · PMID 41122884I1
  233. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-68. doi:10.1161/01.cir.92.7.1954 · PMID 7671380H1
  234. Wijtvliet EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, Rienstra M, Folkeringa RJ, et al. Nurse-led vs. usual-care for atrial fibrillation. Eur Heart J. 2020;41(5):634-641. doi:10.1093/eurheartj/ehz666 · PMID 31544925D4
  235. Writing Committee Members, Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83(1):109-279. doi:10.1016/j.jacc.2023.08.017 · PMID 38043043G1
  236. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. doi:10.1056/NEJMoa021328 · PMID 12466506G2
  237. Xie Y, Li W, Meng Y, Huang T, Zheng Y, Huisman MV, et al. Development and External Validation of the GLORIA-AF Bleeding Weighted Risk Score for Patients with Atrial Fibrillation. Eur J Prev Cardiol. 2026;pii: zwag447. doi: 10.1093/eurjpc/zwag447. doi:10.1093/eurjpc/zwag447 · PMID 42667266G3
  238. Xie Y, Li W, Meng Y, Huang T, Zheng Y, Huisman MV, et al. Development and validation of the GLORIA-AF Stroke Weighted Risk Score for patients with atrial fibrillation. Europace. 2026;28(10). doi:10.1093/europace/euag236 · PMID 42667264G3
  239. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med. 2019;381(12):1103-1113. doi:10.1056/NEJMoa1904143 · PMID 31475793C6G2
  240. Yokose M, Sangawa M, Shiomi H, Sakamoto K, Iijima K, Kawaji T, et al. Initial Dose of Intravenous Atropine for Patients With Symptomatic Bradycardia　- A Scoping Review. Circ Rep. 2025;7(11):1044-1050. doi:10.1253/circrep.CR-25-0169 · PMID 41216404I1
  241. Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, et al. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41(36):3437-3447. doi:10.1093/eurheartj/ehaa226 · PMID 32372094G3
  242. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126. doi:10.1093/eurheartj/ehac262 · PMID 36017572B6C9D1D4G1H3
  243. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. doi:10.1136/bmj.h4451 · PMID 26321114I1
  244. Zimerman A, Dal Forno A, Rohde LE, Ternes CM, Alves FD, Damiani LP, et al. Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial. JAMA Cardiol. 2026;11(4):360-368. doi:10.1001/jamacardio.2026.0101 · PMID 41811324C5

Otros documentos con DOI (3)

  1. Cózar-León R, García-Fernández FJ, Navarro-Manchón J, Fontenla A, Molina-Lerma M, Calvo D. Registro español de marcapasos. XXIII informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2025). Revista Española de Cardiología. 2026. doi:10.1016/j.recesp.2026.07.005G3
  2. Jiménez-Candil J, González VB, Rueda EA, Asensi JO, Calvo D. Registro español de desfibrilador automático implantable. XXII informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2025). Revista Española de Cardiología. 2026. doi:10.1016/j.recesp.2026.06.020G3
  3. Rubio-Campal JM, García BC, Amador PB, Rodríguez-Entem F, Cuervo DC. Registro español de ablación con catéter. XXV informe oficial de la Asociación del Ritmo Cardiaco de la Sociedad Española de Cardiología (2025). Revista Española de Cardiología. 2026. doi:10.1016/j.recesp.2026.07.011G3H2

Fichas técnicas (CIMA, AEMPS) (30)

  1. Ficha técnica de acenocumarol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 58994B5C1C4C5I1I2
  2. Ficha técnica de adenosina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 60375I1I2
  3. Ficha técnica de amiodarona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 48048C1C4C5I1I2
  4. Ficha técnica de amiodarona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 54723I1I2
  5. Ficha técnica de andexanet alfa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 1181345001I2
  6. Ficha técnica de apixaban. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 111691009B5C1C4C5I1
  7. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 55529C4
  8. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 56777I1
  9. Ficha técnica de atenolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 56967I1
  10. Ficha técnica de atropina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 85535I1
  11. Ficha técnica de bisoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 57655C4I1
  12. Ficha técnica de dabigatran. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 08442011B5C1C4C5I1
  13. Ficha técnica de digoxina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 34566C4I1I2
  14. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 55285C4I1
  15. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 58483C4
  16. Ficha técnica de diltiazem. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 59911I1
  17. Ficha técnica de dronedarona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 09591003C1C4C5I1I2
  18. Ficha técnica de edoxaban. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 115993018B5C1C4C5I1
  19. Ficha técnica de flecainida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 57514I1
  20. Ficha técnica de flecainida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 57532C1C4C5I1I2
  21. Ficha técnica de ivabradina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 05316010I1
  22. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 54503C4I1
  23. Ficha técnica de metoprolol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 56989I1
  24. Ficha técnica de propafenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 55538C1C4C5I1I2
  25. Ficha técnica de rivaroxaban. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 08472018B5C1C4C5I1
  26. Ficha técnica de sotalol. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 62001C1C4C5I1I2
  27. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 39784I1I2
  28. Ficha técnica de verapamilo. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 50891C4I1
  29. Ficha técnica de vernakalant. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 10645002I1I2
  30. Ficha técnica de warfarina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 19/10/2026. CIMA, registro 63062B5C4C5I1I2
La lista se genera sola a partir de lo que citan los módulos (PubMed por PMID, DOI resuelto en PubMed o en CrossRef, CIMA y ClinicalTrials.gov) y se rehace al regenerar el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.